Calls of the Day: Abbvie, Vertex, Veeva and Vistra

Group 1: Biotech Sector - Wolf expresses a bullish outlook on the biotech sector, indicating significant upside potential for the group [1] - Abby and Vertex are highlighted as companies with multiple approved drugs generating revenue, contrasting with typical biotech firms that may rely on a few products awaiting FDA approval [2][3] - Abby is noted for its mid-teens valuation multiple and approximately 3% dividend yield, while Vertex has a recently approved pain medication that enhances its attractiveness [3][4] Group 2: Healthcare Sector - JP Morgan upgrades Viva to overweight, emphasizing its role as a cloud-based software provider for the life sciences sector [5] - Viva has demonstrated consistent revenue growth, with last quarter's growth at 16%, and prior years at 15% and 14% respectively, while maintaining a balanced revenue exposure of 50% in the US and 50% internationally [6] - Viva's market capitalization is around $45 billion, and its stock is currently trading about 15% below its all-time high from August 2021 [6] Group 3: Utility Sector - Roth Capital shows a bullish stance on Vistra, which is one of the three utility names owned by the company, alongside Constellation and Atmos Energy [7] - The utility sector is experiencing a pullback, with Vistra and Constellation both seeing declines of just over 1.5% [7]